April 2021

Olive Farms Biodiversity:Verbascum thapsus

By |2021-04-13T12:02:12+03:00April 13th, 2021|Categories: Olive Farms Biodiversity|Tags: , |

Verbascum thapsus Properties Versatile, fuzzy mullein is a gardener’s friend, an herbalist’s delight and an engineering marvel all on its own. A member of the snapdragon family, mullein has flowers that are flat and open, unlike the irregular “dragon faces” of snapdragons. Within the Scrophulariaceae family, the genus Verbascum consists of about 300 species native to Europe, West and Central Asia, and North Africa. Most are tall, stout biennials with large leaves and flowers in long terminal spikes. The species best-known among herbalists is the homely but useful common mullein, V. thapsus. First-year plants form a rosette of large, velvety leaves up to 1 foot long. In the second year, a velvety flower spike grows to 8 feet tall. The stalk has alternate leaves that clasp the stem, a nifty arrangement that directs rainwater down the stem to the roots. From June to September, five-petaled yellow flowers 1/4 to 1 inch across bloom randomly in the dense, club-shaped terminal cluster. The three upper stamens, which are short and woolly, contain a sap that lures insects to the plant. The two lower stamens, which are longer and smooth, produce the pollen that fertilizes the flower. Several mullein species with more attractive leaves or [...]

Olive Farms Biodiversity :Crataegus Monogyne

By |2021-04-13T11:13:08+03:00April 8th, 2021|Categories: Olive Farms Biodiversity|Tags: , , |

Crataegus in the treatment of cardiovascular disease Results recorded from clinical trials, experiences of professionally qualified medical herbalists, and the low/negligible incidence of side effects experienced by patients would indicate that Crataegus preparations hold significant potential as a useful remedy in the treatment of CVD. Clinical trials have until recently been largely confined to patients presenting with NYHA stage I or II heart failure. More recently, the inclusion of patients with more advanced CVD in clinical trials might have affected outcomes, particularly where dosages were not adjusted to reflect the severity of illness. Studies by Holusbarsch et al.[35] would indicate efficacy of Crataegus preparations in the treatment of mild to moderate heart failure (NYHA I–II). The more seriously ill patient may need higher dosages (1800 mg) as used by Tauchert[36] for significant improvements to be obtained. Ultimately, an examination of the data to date is encouraging but would point to the need for a more targeted approach in terms of dosage related to severity of illness. It is possible that this remedy might have limited the benefit for more seriously ill patients but, used in the early stages of disease progression, may significantly enhance prognosis. The excellent safety profile of this remedy, coupled with the lack of [...]

Go to Top